Core organic revenue grew nearly 10% in H1 2026, led by Aerospace & Defense, IGT, and Medical, offsetting automotive weakness. Margins and EPS improved, with continued benefits from the Optimise program and strong cash generation. Full-year outlook remains positive, with further margin expansion expected.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.